share_log

Invivyd Class Action: Levi & Korsinsky Reminds Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of April 3, 2023 - IVVD

Invivyd Class Action: Levi & Korsinsky Reminds Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of April 3, 2023 - IVVD

Invivyd 集体诉讼:Levi & Korsinsky 提醒 Invivyd, Inc. f/k/A Adagio Therapeutics, Inc. 投资者注意未决的集体诉讼,首席原告的最后期限为 2023 年 4 月 3 日——IVVD
newsfile ·  2023/02/08 14:14

New York, New York--(Newsfile Corp. - February 8, 2023) - Levi & Korsinsky, LLP notifies investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or the "Company") (NASDAQ: IVVD) of a class action securities lawsuit.

纽约,纽约-(Newsfile Corp.-2023年2月8日)-Levi&Korsinsky,LLP通知投资者Invivyd,Inc.f/k/a Adagio治疗公司(“因维达”或“公司”)(纳斯达克:IVVD)的集体证券诉讼。

The lawsuit on behalf of Invivyd investors has been commenced in the the United States District Court for the District of Massachusetts. This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive. Follow the link below to get more information and be contacted by a member of our team:

代表Invivyd投资者的诉讼已经在美国马萨诸塞州地区法院开始。这起诉讼是代表2021年11月29日至2021年12月14日期间(包括首尾两天)购买Adagio普通股的所有买家。点击下面的链接获取更多信息,并与我们团队的一名成员联系:

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

或联系约瑟夫·E·利维,Esq.通过电子邮件jlevi@levikorsinsky.com或电话(212)363-7500。对你来说没有任何费用或义务。

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. NEWS - IVVD NEWS

Invivyd,Inc.f/k/a Adagio治疗公司新闻-IVVD新闻

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

案例详情:起诉书称,被告做出虚假陈述和/或隐瞒:(A)被告用来声称针对新冠肺炎的研究性单抗治疗药物ADG20对奥密克戎有效的表位映射、结构研究和序列分析不充分、不可靠,也不足以声称ADG20对奥密克戎有效;(B)被告关于ADG20对奥密克戎有效的说法缺乏合理的事实依据;以及(C)ADG20对奥密克戎变体的有效性是其对先前变体的有效性的300多倍。

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Invivyd during the relevant timeframe, you have until April 3, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

这对股东意味着什么:如果您在相关时间段内在Invivyd遭遇损失,您必须在2023年4月3日请求法院指定你为主要原告。你有能力分享任何赔偿,并不需要你担任主要原告。

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

您无需支付任何费用:如果你是班级成员,你可能有权获得补偿,而无需支付任何自掏腰包的成本或费用。与我们的法律团队讨论您的权利,无需支付费用或义务。

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form or call 212-363-7500 to discuss the case.

保护您的财务利益:填写这份简短的提交表格或致电212-363-7500讨论此案例。

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

为什么是Levi&Korsinsky:在过去20年里,Levi&Korsinsky的团队为愤愤不平的股东争取了数亿美元,并建立了赢得高风险案件的记录。我们公司拥有在复杂的证券诉讼中代表投资者的广泛专业知识,并拥有一支70多名员工的团队为我们的客户服务。连续七年,Levi&Korsinsky在ISS证券集体诉讼服务公司的前50名报告中被列为美国最大的证券诉讼公司之一。

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

联系方式:
Levi&Korsinsky,LLP
约瑟夫·E·利维,Esq.
埃德·科辛斯基,Esq.
百老汇55号,10楼
纽约州纽约市,邮编:10006
邮箱:jlevi@levikorsinsky.com
电话:(212)363-7500
传真:(212)363-7171

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发